The projected fair value for CRISPR Therapeutics is US$83.24 based on 2 Stage Free Cash Flow to Equity CRISPR Therapeutics' US$45.55 share price signals that it might be 45% undervalued The analyst ...

Back in 1900 the life expectancy of people with Down Syndrome was 9 years. In 1984, it was 28 years, today it's leveled off ...

In a step toward treating mitochondrial diseases, researchers in the Netherlands have successfully edited harmful mutations ...

A new study highlights a historic step in personalized medicine, utilizing CRISPR gene-editing technology for a ...

Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced the successful mapping of ...

Scientific organizations recently called for a 10-year ban on human germline editing. But will we ever be ready? And how ...

CRISPR-Cas systems are prokaryotic immune systems that confer resistance to foreign genetic elements such as plasmids and phages. CRISPR-Cas systems have been exploited for targeted genome editing.

A novel, portable assay can deliver TB diagnoses in under an hour at low cost using samples of blood, saliva, or sputum, ...

They also found that after the extra chromosome was removed, genes tied to nervous system development were more active and ...

We're a step closer to two men being able to have genetic children of their own after the creation of fertile mice by putting ...

Moving toward clinical development, the researchers demonstrated efficient delivery of mRNA mitochondrial base editors using lipid nanoparticles.